AS/Spondyloarthritis
Dr. John Cush RheumNow
3 years 10 months ago
Peripheral SpA: Dr. Antoni Chan and Dr. Nelly Ziade
Dr. Chan ( @synovialjoints) interviews Dr. Ziade about abstract #1787 presented at the #ACR21 annual meeting.
https://t.co/Sdd1HHKRib https://t.co/ynRocjviVu
Robert B Chao, MD doctorRBC
3 years 10 months ago
ePROs for SpA patients showed a trend in reduction of disease activity, improved clinic workload, individualized treatment with good patient/physician user satisfaction
Abs#1788
#ACR21 @RheumNow
https://t.co/04kUikdIZu https://t.co/uO9junUqKi
Aurelie Najm AurelieRheumo
3 years 10 months ago
Avoid IFX drug holidays!
In this study 400+ pts
Dvlpmt of ADAs associated w/
▶️RA vs. SPA OR 2.1
▶️Smoking OR 1.8
▶️Drug holidays > 11 weeks OR 4.1
▶️High DA OR 1.5
while
◀️Concomitant IS drug OR 0.4
◀️ IFX dose increments OR 0.4, were protective #ACR21 @RheumNow #Abst1525 https://t.co/cxx7aWX5wh
Mrinalini Dey DrMiniDey
3 years 10 months ago
Safety profile of #upadacitinib in #RA, #PsA, #AnkylosingSpondylitis
👉🏼AE rates similar across UPA, ADA & MTX in RA, and UPA & ADA in PsA
👉🏼No new safety risks with long-term use
👉🏼#Herpeszoster & incr CPK more common w/ UPA vs ADA/MTX
Abs#1691 #ACR21 @RheumNow https://t.co/tKYi65kB5r
Mrinalini Dey DrMiniDey
3 years 10 months ago
Watch my video summary of abstracts #0380 and #0381 presented at the #ACR21 on #SickLeave and #WorkDisability in #axSpA by @ElenaNikiUK and colleagues.
@RheumNow https://t.co/HWEyPoPJi0
sheila RHEUMarampa
3 years 10 months ago
For Dr @LianneGensler managing axSpA requires a sundae🍨approach! How cool is that?!😎
This means that we need to take a holistic approach on the management of axSpA - both non/pharmacologic & there's no one magic pill to treat the disease.
@RheumNow #ACR21 #RheumTwitter https://t.co/o0OjcEn16b
Dr. John Cush RheumNow
3 years 10 months ago
Sick Leave and Work Disability in Patients with AxSpA: Dr. Mrinalini Dey ( @DrMiniDey) discusses abstracts #0380 and #0381 presented at the #ACR21 annual meeting.
https://t.co/Wm4qpxerYJ https://t.co/6CwPrZjqJT
Uveitis is the most frequent extra-musculoskeletal manifestation (EAM) in Axial Spondyloarthritis (axSpA). The prevalence of uveitis in axSpA is between 25-30%. Up to 50% of patients with an acute episode of uveitis develop recurrent anterior uveitis or iritis. Being such a prevalent EAM in axSpA, we should focus on this condition. There have been some updates on uveitis in SpA at #ACR21 which I will share here.
swethaann23 swethaann23
3 years 10 months ago
Findings:
1. 21% of the patients in the Ankylosing Spondylitis Registry of Ireland (ASRI) were unemployed which is higher than their national average.
2. Stong predictors of unemployment were - Male sex and worse disease activity outcome measures(BASMI and ASQoL)
#ACR21 @RheumNow
swethaann23 swethaann23
3 years 10 months ago
#ACR21 @RheumNow
Abst#0359 by Garrido-Cumbrera et al. has mapped out the journey from symptom onset to diagnosis of axSpA across 13 European countries.
swethaann23 swethaann23
3 years 10 months ago
#ACR21 @RheumNow
Abst#0364 by Wetterslev et al. sought to identify axSpA characteristics of patients tapered off TNFI and showed clinical and radiographic improvement.
🔽52% were tapered off
⭐️The highest predictor of success is a low physician global VAS score
Robert B Chao, MD doctorRBC
3 years 10 months ago
⭐️AxSpA pts with decrease in oral microbial diversity
⭐️Immune response to oral/fecal microbes altered in AxSpA pts.
⭐️HLA-B27 associated ⬆️IgA coated microbes, may contribute to development of AxSpA
Abs#0052
https://t.co/NQgm0lpYJj
#ACR21
@RheumNow
Pedro Castillo _Castillo_Pedro
3 years 10 months ago
Year 2 f/u on PsA, axSpA, or RA using CT-P13, an infliximab (IFX) biosimilar. Pts either naive to IFX or switched from IFX:
💠IFX-naive: improved disease activity
💠IFX-switched: maintained stable disease
💠No new safety concerns
https://t.co/VGBicnq15w
#ACR21 Abst#0817 @RheumNow
Poster Hall